The directed differentiation of human pluripotent stem cells (hPSCs) has the potential to produce beta cells for transplantation into diabetics. However, the available protocols for in vitro differentiation produce only 'beta-like' cells. These beta-like cells do not perform the accurate glucose-stimulated insulin secretion (GSIS) found in mature beta cells unless they are transplanted into mice and allowed to further differentiate for many weeks 1 . During normal development, insulin-expressing beta cells appear around embryonic day 13.5 (E13.5) in mice or week 8 and 9 post-conception in humans 2, 3 , but regulated GSIS has been observed only days after birth. The signals and mechanisms governing beta-cell maturation, either during postnatal development or after transplantation, are unknown.
In this study, we sought to define functional beta-cell maturation based on GSIS parameters, and to identify markers of functionally mature beta cells that could be used to make functional hPSC-derived beta cells in culture.
Traditionally, GSIS is measured by the fold change in insulin secretion between low (2.8-5 mM) and high (>10 mM) glucose concentrations 4 . In this assay, neonatal beta cells display a high basal insulin secretion at low glucose concentrations, and stimulation with a high concentration of glucose results in a small fold-increase in insulin secretion. These data could be explained if neonatal beta cells have uncontrolled insulin 'leakiness' at low glucose concentrations, or alternatively, if they have a lower glucose concentration threshold at which they secrete insulin. To distinguish between these two hypotheses, we conducted dynamic GSIS assays on neonatal (1 d old, P1) and older (15 d old, P15) mouse islets using a very low baseline glucose level of 0.5 mM. Neonatal P1 islets execute a full GSIS functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3 Insulin-expressing cells that have been differentiated from human pluripotent stem cells in vitro lack the glucose responsiveness characteristic of mature beta cells. Beta-cell maturation in mice was studied to find genetic markers that enable screens for factors that induce bona fide beta cells in vitro. We find that functional beta-cell maturation is marked by an increase in the glucose threshold for insulin secretion and by expression of the gene urocortin 3.
response (both first and second phases of insulin secretion) at low (2.8 mM) glucose concentrations, whereas P15 islets have no response (no insulin secretion) at this concentration (Fig. 1a) . These results show that immature beta cells are not leaky, but rather have a lower threshold for GSIS, secreting insulin in response to a lower glucose concentration than mature beta cells.
To determine when beta cells acquire a mature GSIS capacity, we tested mouse islets isolated from P1 to adult for their response to low (2.8 mM) and high (16.7 mM) glucose concentrations. Islets from neonatal mice, ages P1 and P2, secreted 2.6-± 0.5-fold more insulin in high glucose than in low glucose, respectively, whereas islets from P9 to adult secreted, on average, 60.9-± 10.7-fold more insulin in high glucose than in low glucose, respectively (Fig. 1b) . Thus, the large change in GSIS response between low and high glucose that characterizes beta-cell maturation occurs between P2 and P9. Islets of mice younger than P2 display an 'immature' response, whereas islets from mice older than P9 respond as 'mature' beta cells. From P3 to P8, a mixed (intermediate) GSIS phenotype was observed.
The differences in insulin secretion between mature and immature beta cells is specific for glucose. The amount of insulin secreted by P1 and P9 islets in response to 20 mM arginine was 11.9 ± 3.5 ng and 10.3 ± 1.1 ng, respectively. The amount of insulin secreted from P1 and P21 islets in response to 30 mM KCl was 9.17 ± 1.4 ng and 5.66 ± 0.9 ng, respectively. These differences are not statistically significant (Fig. 1c) . In contrast, islets from P1 mice secreted only 6.2 ± 0.6 ng insulin, during 75 min in 0.5 ml high (16.7 mM) glucose, whereas the same number of islets from P9 and P21 mice secreted 23.7 ± 5.7 ng and 19.7 ± 3.2 ng insulin, respectively (difference between P1 and older mice, P < 0.001). At low glucose levels, the opposite trend was observed: P1 islets secrete 1.8 ± 0.5 ng insulin at 2.8 mM glucose, whereas P9 and P21 islets secrete only 0.4 ± 0.3 ng and 0.3 ± 0.1 ng insulin, respectively (P < 0.05) (Fig. 1c) .
We examined the physiological consequences in vivo of the differences observed in vitro between mature and immature beta cells' response to glucose. In agreement with previous reports 4 , P1 pups had significantly lower blood glucose levels than P14 pups. The average blood glucose concentration at P1 is 3 mM, whereas blood glucose at P14 averages 6.2 mM (P < 2.5 × 10 −24 ) (Fig. 1d) . Notably, the average blood glucose level in P1 pups is higher than the glucose concentration that causes insulin secretion in vitro in P1 islets. If the in vitro observation that immature beta cells secrete insulin at low glucose levels (Fig. 1a) holds true in vivo, one should see higher insulin in the blood of neonates. Consistent with this prediction, the P1 pups had nearly twofold higher levels of insulin in their blood than P14 animals ( Fig. 1e) , although we note that there is a high variability of blood insulin in nonfasted animals. We also examined insulin granules in beta cells at each stage using electron microscopy ( Fig. 1f,g ). P1 beta cells contained approximately twofold fewer insulin granules compared with P10 beta cells, suggesting a mechanistic difference in insulin secretion. To find molecular markers whose expression pattern correlates with beta-cell maturation, we sorted beta cells expressing Pdx1-EGFP from P1 or P10 animals by fluorescence-activated cell sorting (FACS) and compared their global gene expression patterns using transcriptional arrays. The Pdx1-EGFP strain was used instead of the insulin-EGFP strain as the latter animals were slightly diabetic. We also analyzed beta cells from E18.5 embryos and adult mice (Fig. 1h) to further reduce the number of genes whose transcriptional differences are not related to GSIS maturation. Notably, the gene expression profiles of functionally mature and immature beta cells tested this way are very similar (Fig. 1i) .
Various Figure 1 Beta-cell maturation is defined by a decrease in GSIS sensitivity to low glucose levels and by the expression of Ucn3. (a) Three independent sets of 50 islets each, from P1 or P15 mice, were sequentially perfused with basal (0.5 mM, gray), low (2.8 mM, blue) or high (16.7 mM, red) glucose in a dynamic GSIS assay. Arrows indicate the time points at which solutions were changed. P1 islets display complete first and second phases of GSIS in response to low glucose, whereas P15 islets do not secrete insulin at this glucose concentration. (b) Triplicates of ten islets from P1 to adult were assayed for GSIS using low glucose (2.8 mM) and high glucose (16.7 mM). Two age groups can be distinguished according to their stimulation index (fold change in GSIS). ***, P < 5 × 10 5 . (c) Three independent sets of ten islets each from P1, P9 or P21 were assayed for GSIS using low glucose (2.8 mM, blue), high glucose (16.7 mM, red), 20 mM arginine (gray) or 30 mM KCl (green). The difference in the amount of insulin secreted between mature and immature islets is specific to glucose. *, P < 0.05; **, P < 0.001; NS, not significant). 
B r i e f c o m m u n i c at i o n s
ATP-regulated K + channel 5, 6 , reduced expression of glucose transporters 6 , low activity of glucokinase 7 or low levels of the beta cell-selective gap junction protein Connexin36 (ref. 8) . Recently, genetic ablation of the transcription factors NeuroD1 in adult mouse beta cells 9 or the combined deletion of Foxa1 and Foxa2 (ref. 10) resulted in beta cells with an immature-like GSIS phenotype. We thus first assessed known beta-cell genes whose expression levels could explain the functional difference between mature and immature beta cells. We examined expression levels of beta-cell transcription factors (Pdx1, Nkx2.2, Nkx6.1, NeuroD1, Foxa1, Foxa2, MafA, MafB and Hnf4a), key proteins involved in glucose sensing and insulin secretion (Glucokinase, Glut2, Cav6.1, Kir6.1, Sur1, Pcsk1 and Pcsk2), the beta cell-selective gap junction Connexin36, and Insulin1 and Insulin2. We also looked at tissue-specific glucose transporters (Glut 1, 3 and 4) and hexokinases (Hexokinase 1, 2 and 3) (Fig. 1j) . The RNA expression levels of most of these genes did not change significantly between immature and mature cells (or change expression by less than twofold, making them unsuitable for on/off detection of mature beta cells). One exception is the transcription factor MafB, which is expressed at 2.5-fold higher levels in immature beta cells, consistent with previous reports 11 .
We next examined all genes for which expression changes by more than twofold between immature and mature cells. We excluded genes for which a significant change in expression also occurred between the younger mice, E18.5 and P1, and the older mice, P10 and adult, thereby focusing on genes that change expression specifically within the time window of beta-cell maturation (groups i and ii in Fig. 1h) . We found 71 genes (81 probes) that were upregulated and 66 genes (72 probes) that were downregulated during beta-cell maturation (Supplementary Table 1) . Of the former group, 36 genes were acinarrelated genes (Supplementary Table 1) , which is best explained by the rapid expansion of exocrine tissue at this stage, thereby increasing the probability of a small acinar cell contamination during FACS sorting and resulting in the misleading indication that acinar genes are upregulated. We chose 16 genes (Supplementary Table 1) for which beta-cell expression had previously been reported and analyzed their protein expression levels using western blot analysis and immunohistochemistry. From all these analyses, one strong candidate emerged: the gene Urocortin 3 (Ucn3).
The levels of Ucn3 mRNA increased more than sevenfold between immature and mature beta cells, and nearly tenfold between E18.5 and adult (Fig. 1k and Supplementary Table 1) . Immunofluorescence staining showed that Ucn3 was highly expressed in all adult beta cells, but was undetectable in islets from E18.5 embryos (Fig. 1l,m) . As with insulin, the signal intensity of Ucn3 protein varies from cell to cell in the adult islet. This variation does not correlate with the variation in insulin intensity as cells that show high staining intensity for insulin show both high and low staining intensities for Ucn3, and vice versa. No co-localization of Ucn3 with glucagon, somatostatin or pancreatic polypeptide (PPY) was observed, indicating beta cell-specific expression of the gene (Supplementary Fig. 1 ). 
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In vitro h i g Ucn3 is a secreted protein expressed in regions of the brain and in the pancreas, and was reported to be exclusively expressed by beta cells but not other endocrine cells in the islet 12 . Secretion of Ucn3 from beta cells is induced by high glucose in adult mice, and the gene has a positive effect on GSIS at high glucose concentrations 12, 13 . We tried to mature fetal beta cells in vitro by culturing them in the presence of recombinant Ucn3 protein for several days, but did not observe any effect of the recombinant protein on the GSIS profile of the cells, suggesting that Ucn3 by itself cannot induce beta-cell maturation (data not shown). It remains to be determined whether Ucn3 knockout mice have beta-cell maturation defects.
We next examined the patterns of Ucn3 expression at additional time points during the period of beta-cell maturation. Ucn3 protein was not detected in any islets of P1 pups (Fig. 2a-f) . At P6, Ucn3 expression is found primarily in large islets, not in small beta-cell aggregates. By P22, Ucn3 protein is strongly detected in all beta cells. Intracellular FACS analysis with antibodies against Ucn3 and insulin was done to quantify the percentage and levels of Ucn3 expression in beta cells. At E18.5, 90.2 ± 1.7% of beta cells express insulin alone, and 9.8 ± 1.7% also stain weakly for Ucn3 (Fig. 2g) . The low expression level of Ucn3 in the small population detected by FACS at this age is probably too low to be detected by conventional immunofluorescence on tissue sections. At P6, 55.1 ± 1.6% of beta cells are either negative for Ucn3 or express low levels of the protein, whereas 44.9 ± 1.6% of beta cells express high levels of both Ucn3 and insulin (Fig. 2h) . By P13, just at the end of the maturation window, 93.5 ± 1.5% of the beta cells express high levels of Ucn3 and only 6.5 ± 1.5% express insulin alone (Fig. 2i) . The increase in Ucn3 in beta cells during maturation is gradual, as can be seen by the shift in the mean Ucn3 signal intensity ( Supplementary  Fig. 2a) . The signal intensity of insulin is unchanged, indicating that expression of insulin protein remains constant throughout this time period (Supplementary Fig. 2b ). This mixed pattern of Ucn3 expression may explain why a marginally mature phenotype was observed between P2 and P9.
Finally, we wished to determine whether UCN3 could serve as a marker for functionally mature beta cells derived from hPSCs. Immunoassaying with antibodies against UCN3 on pancreatic sections obtained from an adult human donor revealed that the gene is expressed by all insulin-positive beta cells and not expressed in glucagon-expressing alpha cells. A small fraction of somatostatin-and PPY-expressing cells also expressed UCN3 (Supplementary Fig. 3) . To see whether UCN3 is induced during the maturation of human embryonic stem cell (hESC)-derived beta cells after transplantation, we differentiated hESCs using a four-step protocol to Pdx1 + and NKX6.1 + pancreatic progenitors (data not shown). These cells were then differentiated in vitro for 3 more days to become insulinpositive beta-like cells (Fig. 2j and Supplementary Methods) . Separately, stage 4 clusters of Pdx + Nkx6.1 + pancreatic progenitors, containing a few insulin-positive beta-like cells, were transplanted to the kidney capsule of severe combined immunodeficient (SCID)-beige mice, where they differentiate further and mature in vivo (Fig. 2j) . A glucose tolerance test done on transplanted animals showed fasting human C-peptide levels above background 12 weeks after transplantation (Supplementary Fig. 4) . Despite high variation in fasting human C-peptide between the transplanted mice, all but one animal (6/7) showed an increase in blood human C-peptide of 1.7-fold to 7.6-fold (average 2.8-± 0.9-fold), demonstrating that the transplanted hESC-derived cells matured to glucose-responsive beta cells. Immunostaining showed that although the in vitro-differentiated beta-like cells expressed insulin, they were negative for UCN3 staining (Fig. 2k,l) . Conversely, the in vivo-matured cells stained positive for both insulin and UCN3 proteins (Fig. 2m) . This expression of human UCN3 in the transplant was exclusive to the beta cells; the UCN3 protein was not detected in any glucagon-, somatostatin-or PPY-expressing cells (Supplementary Fig. 5) .
In summary, we propose an operational definition for mature beta cells based on changing glucose thresholds for GSIS response during development. We also identify a molecular marker, Ucn3, that distinguishes mature and immature beta cells. Notably, we find that UCN3 is induced in hESC-derived beta cells after maturation in vivo. High-throughput screening can now use the difference in GSIS and the expression of Ucn3 as benchmarks in studies aimed at finding conditions to induce functional beta-cell maturation in vitro.
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